Estimated Wasteful Spending on Aducanumab Dispensing in the U.S. Medicare Population
A Cross-Sectional Analysis
Published in: Journal of the American Geriatrics Society (2022). doi: 10.1111/jgs.17891
Posted on RAND.org on August 11, 2022
Aducanumab, a weight-dosed Alzheimer's drug with uncertain benefits and high cost, could strain Medicare's budget if approved for widespread use. In April 2022, Medicare issued a final determination restricting aducanumab's use to clinical trials. However, Medicare's coverage decision may still be overturned by legal challenges, potentially leading to much higher uptake. Moreover, several other Alzheimer's infusion drugs similar to aducanumab are currently in the development pipeline.
Because aducanumab is available in two fixed-dose vial sizes, its use may result in large amounts of discarded drug and wasteful spending. To quantify the amount of discarded drug and potential savings that could be generated from more efficient aducanumab vial sizes, we analyzed patient weight distributions from a nationally representative sample of Medicare beneficiaries with mild cognitive impairment (MCI) or mild dementia.
Research conducted by
This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.